New combo therapy aims to beat relapsed blood cancers
NCT ID NCT04375631
First seen Mar 16, 2026 · Last updated Jun 23, 2026 · Updated 17 times
Summary
This phase 1 trial tests giving a powerful chemotherapy combination (CLAG-M or FLAG-Ida) immediately followed by a reduced-intensity stem cell transplant for adults with myeloid cancers that have come back or not responded to treatment. The goal is to find the best dose of total body irradiation to safely kill cancer cells and make room for donor stem cells. Up to 120 participants will be enrolled, and researchers will monitor for graft failure, disease progression, and side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT ACUTE MYELOID LEUKEMIA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fred Hutch/University of Washington Cancer Consortium
RECRUITINGSeattle, Washington, 98109, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Chemotherapy (cladribine, cytarabine, filgrastim, mitoxantrone or idarubicin, fludarabine) plus total body irradiation, followed by donor stem cell transplant
What this could lead to
If successful, this approach could offer a more effective treatment option for patients with myeloid cancers that have relapsed or not responded to standard therapy.
What could go wrong
This is an early phase 1 trial, so the main goal is finding a safe dose, not proving it works. There are serious risks like graft failure, severe graft-versus-host disease, and infections.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.